 |
Prospector
Profile
07.1144
|
| |
| Incyte Corporation |
NAICS |
541710 |
| Route 141 & Henry Clay Road, Building E336
Wilmington, DE 19880 |
Description |
Biotechnology |
| (302) 498-6700 |
Employees |
186 |
| http://www.incyte.com/ |
Revenue |
(mil) |
27.6400 |
| |
Income |
(mil) |
-74.1700 |
| |
Assets |
(mil) |
353.6000 |
| |
Liability |
(mil) |
438.5100 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Incyte Corp. posted an $18,439,000 net loss on $10,576,000 of total revenues for the second quarter ended June 30, 2007, as compared with a $20,520,000 net loss on $6,855,000 of total revenues for the same period last year. At June 30, 2007, the company's balance sheet showed $308,798,000 in total assets and $428,433,000 in total liabilities, resulting in a $119,635,000 stockholders' deficit.
|
| |
|
Intellectual Property:
The Company has established a patent portfolio of owned or in-licensed patents and patent applications that cover aspects of all its drug candidates, as well as other patents and patent applications that relate to full-length genes and genomics-related technologies obtained as a result of its past high-throughput gene sequencing efforts. The patents and patent applications relating to drug candidates generally include claims directed to the drug candidates, methods of using the drug candidates, formulations of the drug candidates, and methods of manufacturing the drug candidates. The Company has a number of established patent license agreements relating to its gene patent portfolio and genomics-related technology patent portfolio. It is presently receiving royalties and other payments under certain gene and genomics-related patent license agreements. [SEC Filing 10-K 02-28-07]
|
| |
|
Description:
The Company develops proprietary small molecule drugs to treat human immunodeficiency virus, diabetes, oncology, and inflammation diseases.
|
| |
|
Officers:
Richard U. Deschutter (Chair); Paul A. Friedman (CEO); David C. Hastings (CFO); Laurent Chardonnet (VP-Finance & Treas.); Barry M. Ariko (Dir.); Julian C. Baker (Dir.); Paul A. Brooke (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock Symbol INCY; NasdaqGM;
84,212,602 common shares outstanding as of July 27, 2007.
|
| |
| |
| |
| return to main page |
|
|
